Flu Vaccine May Hold Key to Preventing Heart Disease


A new study in Vaccine explains how flu vaccines prevent heart attacks

Amsterdam, October 21, 2014

Flu vaccines are known to have a protective effect against heart disease, reducing the risk of a heart attack. For the first time, this research, published in Vaccine, reveals the molecular mechanism that underpins this phenomenon. The scientists behind the study say it could be harnessed to prevent heart disease directly.

Heart disease is the leading cause of death worldwide. People can reduce their risk of heart disease by eating healthily, exercising and stopping smoking. However, to date there is no vaccine against heart disease.

Previous clinical findings show that people that receive the seasonal flu vaccine also benefit from its protective effect against heart disease; the risk of having a heart attack in the year following vaccination is 50% lower than people who did not receive the vaccination. The exact mechanism underlying this protective effect remained unknown.

This new study for the first time reveals this mechanism, showing that the flu vaccine stimulates the immune system to produce antibodies that switch on certain processes in cells. These processes lead to the production of molecules that protect the heart. The researchers say that based on the results it may be possible to develop a new vaccine against heart disease.

"Even though the protective effect of the flu vaccine against heart disease has been known for some time, there is very little research out there looking at what causes it. Our proposed mechanism could potentially be harnessed in a vaccine against heart disease, and we plan to investigate this further," said Dr. Veljkovic, Institute Vinca, Belgrade, the lead author of the new study.

The researchers identified a protein called the bradykinin 2 receptor (BKB2R), which is involved in cellular processes that protect the heart. Some of the antibodies the body produces after flu vaccination switch this protein on, therefore protecting against heart disease. The researchers analysed 14 flu viruses used in vaccines, and identified four that could be investigated for use in potential heart disease vaccines.

"The rate of administering flu vaccinations is disappointingly low, even in developed countries," added Dr. Veljkovic "We hope that our results will encourage more people to get vaccinated before the flu season starts."

This article is "Influenza vaccine as prevention of cardiovascular diseases: Possible molecular mechanism", by Veljko Veljkovic, Sanja Glisic, Nevena Veljkovic, Tijana Bojic, Ursula Dietrich, Vladimir R. Perovic, Alfonso Colombatti (doi: 10.1016/j.vaccine.2014.07.007). The article appears in Vaccine, published by Elsevier. http://www.sciencedirect.com/science/article/pii/S0264410X14009335

--

Notes for editor
Full text of the article is available to credentialed journalists upon request, contact newsroom@elsevier.com . Journalists wishing to interview the authors may contact Dr. Veljko Veljkovic at vv@vinca.rs.

About Vaccine
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society, The International Society for Vaccines and The Japanese Society for Vaccinology.www.elsevier.com/locate/vaccine

About Elsevier
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a world-leading provider of information and analytics to professionals and business customers, in a wide range of industries. www.elsevier.com

Media contact
Sacha Boucherie
Sr. Press Officer, Elsevier
+31 20 485 3564
s.boucherie@elsevier.com